BlueCrest Capital Management’s AbbVie ABBV Stock Holding History

BlueCrest Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-11,600	Closed	-$670K	–	536
2014 Q3	$670K	Buy	+11,600	New	+$644K	0.03%	382

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

BlueCrest Capital Management's ABBV Position: Q1 2024 in Review

BlueCrest Capital Management sold out of AbbVie (ABBV) in Q1 2024, closing a stake of 10,400 shares — an estimated $1.79M sold.

BlueCrest Capital Management first reported a position in ABBV in Q2 2015 and held it in 14 quarters. The position peaked at $5.84M in Q2 2018. 3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

BlueCrest Capital Management reported no remaining AbbVie position as of Q1 2024 after selling out during the quarter.
BlueCrest Capital Management sold 10,400 AbbVie shares in Q1 2024, an estimated $1.79M.
BlueCrest Capital Management first reported a position in AbbVie in Q2 2015 and held it in 14 quarters.
BlueCrest Capital Management's AbbVie position peaked at $5.84M in Q2 2018.
3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on BlueCrest Capital Management's 13F filing for Q1 2024, filed 15 May 2024.